Glycopyrronium 320μg/mL in children and adolescents with severe sialorrhoea and neurodisabilities: An open-label study extension of the SALIVA trial

被引：0
|
作者：
不详
机构：
来源：
DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY | 2025年 / 67卷 / 04期
关键词：
D O I：
10.1111/dmcn.16268
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：E85 / E85
页数：1
相关论文
共 50 条
  • [1] Glycopyrronium 320 μg/mL in children and adolescents with severe sialorrhoea and neurodisabilities: An open-label study extension of the SALIVA trial
    Fayoux, Pierre
    Dinomais, Mickael
    Shaw, Helen
    Villain, Frederic
    Schwartz, Deborah
    Gautheron, Vincent
    Letellier, Guy
    Auvin, Stephane
    DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY, 2025,
  • [2] Glycopyrronium 320 μg/mL in children and adolescents with severe sialorrhoea and neurodisabilities: A randomized, double-blind, placebo-controlled trial
    Fayoux, Pierre
    Dinomais, Mickael
    Shaw, Helen
    Villain, Frederic
    Schwartz, Deborah
    Rondeau, Stephane
    Letellier, Guy
    Auvin, Stephane
    DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY, 2024, 66 (07): : 910 - 918
  • [3] Randomised, double-blind, placebo-controlled trial of glycopyrronium in children and adolescents with severe sialorrhoea and neurodisabilities: protocol of the SALIVA trial
    Fayoux, Pierre
    Dinomais, Mickael
    Shaw, Helen
    Probert, Nick
    Villain, Frederic
    Pouchain, Denis
    Texier, Nathalie
    Auvin, Stephane
    BMJ PAEDIATRICS OPEN, 2023, 7 (01)
  • [4] An Open-Label Trial of Risperidone in Children and Adolescents with Severe Mood Dysregulation
    Krieger, Fernanda Valle
    Pheula, Gabriel Ferreira
    Coelho, Roberta
    Zeni, Thamis
    Tramontina, Silza
    Zeni, Cristian Patrick
    Rohde, Luis Augusto
    JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2011, 21 (03) : 237 - 243
  • [5] An Open-Label Extension Study of the Safety and Efficacy of Risperidone in Children and Adolescents with Autistic Disorder
    Kent, Justine M.
    Hough, David
    Singh, Jaskaran
    Karcher, Keith
    Pandina, Gahan
    JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2013, 23 (10) : 676 - 686
  • [6] AGOMELATINE IN CHILDREN AND ADOLESCENTS WITH MODERATE TO SEVERE MAJOR DEPRESSIVE DISORDER: 2-YEAR OPEN-LABEL EXTENSION STUDY
    Falissard, B.
    Buitelaar, J. K.
    Fegert, J. M.
    Penelaud, P. F.
    Marx, U.
    Picarel-Blanchot, F.
    Arango, C.
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 2023, 57 (01): : 138 - 138
  • [7] An open-label trial of risperidone in children and adolescents with bipolar disorder
    Biederman, J
    Mick, E
    Wozniak, J
    Aleardi, M
    Spencer, T
    Faraone, SV
    JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2005, 15 (02) : 311 - 317
  • [8] An open-label pharmacokinetic trial of nefazodone in depressed children and adolescents
    Magnus, RD
    Findling, R
    Preskorn, SH
    Friesen, S
    Marcus, R
    Marathe, P
    DAmico, F
    PSYCHOPHARMACOLOGY BULLETIN, 1997, 33 (03) : 550 - 550
  • [9] An open-label trial of divalproex in children and adolescents with bipolar disorder
    Wagner, KD
    Weller, EB
    Carlson, GA
    Sachs, G
    Biederman, J
    Frazier, JA
    Wozniak, P
    Tracy, K
    Weller, RA
    Bowden, C
    JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2002, 41 (10): : 1224 - 1230
  • [10] Methotrexate and azathioprine in severe atopic dermatitis: a randomized controlled trial and open-label extension study
    Roekevisch, E.
    Schram, M. E.
    Gerbens, L. A. A.
    Hamann, S. A. S.
    Leeflang, M. M. G.
    Brouwer, M. W. D.
    Bos, J. D.
    Spuls, P. I.
    BRITISH JOURNAL OF DERMATOLOGY, 2018, 179 (01) : E45 - E45
12345